EA201400067A1 - Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента - Google Patents

Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента

Info

Publication number
EA201400067A1
EA201400067A1 EA201400067A EA201400067A EA201400067A1 EA 201400067 A1 EA201400067 A1 EA 201400067A1 EA 201400067 A EA201400067 A EA 201400067A EA 201400067 A EA201400067 A EA 201400067A EA 201400067 A1 EA201400067 A1 EA 201400067A1
Authority
EA
Eurasian Patent Office
Prior art keywords
apomorphin
active ingredient
composition containing
therapeutic composition
new therapeutic
Prior art date
Application number
EA201400067A
Other languages
English (en)
Other versions
EA025870B1 (ru
Inventor
Майкл Дей
Джоэль Ричард
Мария-Мадлен Бароннет
Натали Мондоли
Лорен Берточчи
Иеремия Харнетт
Original Assignee
Британния Фармасьютикалс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Британния Фармасьютикалс Лимитед filed Critical Британния Фармасьютикалс Лимитед
Publication of EA201400067A1 publication Critical patent/EA201400067A1/ru
Publication of EA025870B1 publication Critical patent/EA025870B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

Изобретение относится к фармацевтической композиции, содержащей апоморфин в качестве активного фармацевтического ингредиента, сорастворитель, антиоксидант, воду, имеющей рН выше 4. Фармацевтическая композиция пригодна для парентерального введения для лечения болезни Паркинсона.
EA201400067A 2011-07-11 2012-07-11 Применение фармацевтической композиции, содержащей апоморфин EA025870B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290320A EP2545905A1 (en) 2011-07-11 2011-07-11 A new therapeutical composition containing apomorphine as active ingredient
PCT/EP2012/002916 WO2013007381A1 (en) 2011-07-11 2012-07-11 A new therapeutical composition containing apomorphine as active ingredient

Publications (2)

Publication Number Publication Date
EA201400067A1 true EA201400067A1 (ru) 2015-02-27
EA025870B1 EA025870B1 (ru) 2017-02-28

Family

ID=46514305

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400067A EA025870B1 (ru) 2011-07-11 2012-07-11 Применение фармацевтической композиции, содержащей апоморфин

Country Status (29)

Country Link
US (4) US11026938B2 (ru)
EP (2) EP2545905A1 (ru)
JP (2) JP6356064B2 (ru)
KR (1) KR101990897B1 (ru)
CN (2) CN103826612B (ru)
AU (1) AU2012283381B2 (ru)
BR (1) BR112014000306B1 (ru)
CA (1) CA2841807C (ru)
CL (1) CL2014000050A1 (ru)
CO (1) CO6870038A2 (ru)
CR (1) CR20140005A (ru)
CU (1) CU24159B1 (ru)
DO (1) DOP2014000003A (ru)
EA (1) EA025870B1 (ru)
EC (1) ECSP14013200A (ru)
GE (1) GEP20196969B (ru)
GT (1) GT201400003A (ru)
IL (1) IL230308A (ru)
IN (1) IN2014DN00090A (ru)
MA (1) MA35411B1 (ru)
MX (2) MX2014000454A (ru)
MY (1) MY168212A (ru)
NI (1) NI201400003A (ru)
PE (1) PE20141539A1 (ru)
SG (1) SG10201605491PA (ru)
TN (1) TN2014000001A1 (ru)
UA (1) UA113962C2 (ru)
WO (1) WO2013007381A1 (ru)
ZA (1) ZA201309711B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
CN104349768B (zh) 2012-06-05 2017-11-07 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
EP2979688A1 (en) 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
EP3237386A2 (en) * 2014-12-23 2017-11-01 Neuroderm Ltd Crystal forms of apomorphine and uses thereof
WO2017055337A1 (en) 2015-09-28 2017-04-06 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
WO2020243538A1 (en) * 2019-05-31 2020-12-03 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
WO2021026421A1 (en) * 2019-08-07 2021-02-11 Aclipse One Inc. Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
WO2021235436A1 (ja) 2020-05-20 2021-11-25 株式会社メドレックス アポモルヒネ含有経皮吸収型製剤
WO2022271537A1 (en) * 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1662566A1 (ru) * 1988-03-05 1991-07-15 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ стабилизации инъекционного раствора апоморфина
JP2822049B2 (ja) * 1989-02-02 1998-11-05 ゼリア新薬工業株式会社 水性製剤組成物
ES2194867T3 (es) * 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6011043A (en) 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US20030008878A1 (en) 2001-03-09 2003-01-09 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
ITMI20011321A1 (it) * 2001-06-22 2002-12-22 Chiesi Farma Spa Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US6939094B2 (en) 2003-01-28 2005-09-06 Macro Technologies Inc. Autonomous power interface for modifying limited rotation speed of a machine
JP2007524605A (ja) 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
AU2007253586A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity
US20080171072A1 (en) * 2006-08-11 2008-07-17 Frank Burczynski Ocular inserts containing apomorphine
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
CN101712675B (zh) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient

Also Published As

Publication number Publication date
KR20140072861A (ko) 2014-06-13
GT201400003A (es) 2017-09-28
NI201400003A (es) 2015-10-12
UA113962C2 (xx) 2017-04-10
EP2731589A1 (en) 2014-05-21
EP2545905A1 (en) 2013-01-16
TN2014000001A1 (en) 2015-07-01
DOP2014000003A (es) 2014-06-01
US20210244724A1 (en) 2021-08-12
CO6870038A2 (es) 2014-02-20
IN2014DN00090A (ru) 2015-05-15
MX2021010046A (es) 2021-09-21
CN108434094A (zh) 2018-08-24
CR20140005A (es) 2014-07-21
MY168212A (en) 2018-10-15
US20140128422A1 (en) 2014-05-08
BR112014000306A2 (pt) 2017-02-07
EA025870B1 (ru) 2017-02-28
US11026938B2 (en) 2021-06-08
KR101990897B1 (ko) 2019-06-19
PE20141539A1 (es) 2014-10-25
US11766431B2 (en) 2023-09-26
MA35411B1 (fr) 2014-09-01
US20180098981A1 (en) 2018-04-12
BR112014000306B1 (pt) 2022-03-29
CA2841807A1 (en) 2013-01-17
ECSP14013200A (es) 2014-04-30
JP2017081947A (ja) 2017-05-18
CL2014000050A1 (es) 2014-08-18
AU2012283381B2 (en) 2017-07-27
GEP20196969B (en) 2019-04-25
JP2014518285A (ja) 2014-07-28
JP6356064B2 (ja) 2018-07-11
AU2012283381A1 (en) 2014-02-06
ZA201309711B (en) 2014-08-27
US20160310480A1 (en) 2016-10-27
MX2014000454A (es) 2014-09-01
IL230308A (en) 2017-04-30
CN103826612A (zh) 2014-05-28
CN103826612B (zh) 2020-07-28
CU20140005A7 (es) 2014-04-24
SG10201605491PA (en) 2016-08-30
WO2013007381A1 (en) 2013-01-17
CA2841807C (en) 2018-02-20
CU24159B1 (es) 2016-03-31

Similar Documents

Publication Publication Date Title
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
NZ608116A (en) Triazine-oxadiazoles
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
NZ607580A (en) N-heteroaryl compounds
EA201792071A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
EA201490573A1 (ru) Соединение бензотиазолона
IN2013DN02555A (ru)
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU